Bristol UFT Review Standards Questioned By Rep. Bliley In Letter To FDA
Executive Summary
Bristol-Myers Squibb's oral colorectal cancer therapy UFT should be available as a "gentler" alternative to regimens containing Pharmacia's Camptosar, House Commerce Committee Chairman Bliley (R-Va.) told FDA in an April 17 letter to Commissioner Henney.
You may also be interested in...
Bristol Vanlev Launch Resources Will Shift To Pravachol; NDA Withdrawn
Bristol plans to reallocate some of the money reserved for the launch of the antihypertensive Vanlev to help revive the cholesterol-lowering agent Pravachol.
Bristol Seeking Two NDAs For UFT Combos In Response To Rebetron Debate
Bristol-Myers Squibb's submission of two separate NDAs for the combination use of UFT and leucovorin appears to be a new filing and approval strategy for the development of bundled multi-ingredient products.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011